CRIS Current Research Information System

MARCONI, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.395
EU - Europa 2.520
AS - Asia 1.969
AF - Africa 231
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 7
SA - Sud America 4
Totale 8.135
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.371
VN - Vietnam 787
GB - Regno Unito 679
IT - Italia 542
CN - Cina 455
SG - Singapore 428
SE - Svezia 408
DE - Germania 285
IN - India 136
IE - Irlanda 123
FR - Francia 94
TG - Togo 91
RU - Federazione Russa 69
BG - Bulgaria 50
ZA - Sudafrica 50
EE - Estonia 48
CI - Costa d'Avorio 47
JO - Giordania 45
FI - Finlandia 44
NG - Nigeria 41
CH - Svizzera 37
BE - Belgio 32
UA - Ucraina 30
ID - Indonesia 28
CA - Canada 23
IR - Iran 20
NL - Olanda 15
GR - Grecia 14
HK - Hong Kong 12
JP - Giappone 12
UZ - Uzbekistan 12
TR - Turchia 9
ES - Italia 7
HR - Croazia 7
AT - Austria 6
AU - Australia 6
EU - Europa 6
LT - Lituania 5
MK - Macedonia 4
PL - Polonia 4
RO - Romania 4
KR - Corea 3
LB - Libano 3
NZ - Nuova Zelanda 3
BD - Bangladesh 2
BR - Brasile 2
HU - Ungheria 2
KZ - Kazakistan 2
LV - Lettonia 2
PE - Perù 2
PH - Filippine 2
PK - Pakistan 2
PT - Portogallo 2
RS - Serbia 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
CZ - Repubblica Ceca 1
EG - Egitto 1
GE - Georgia 1
IL - Israele 1
KG - Kirghizistan 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MY - Malesia 1
PA - Panama 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
TM - Turkmenistan 1
UG - Uganda 1
Totale 8.135
Salva come PNG Salva come JPEG
Città #
Dong Ket 639
Southend 631
Chandler 438
Singapore 380
Ann Arbor 292
Fairfield 264
Ashburn 226
Houston 147
Santa Clara 147
Wilmington 144
Woodbridge 137
Seattle 129
Dublin 122
Boardman 120
Princeton 118
Cambridge 109
Bologna 97
Lomé 91
Beijing 83
New York 64
Nanjing 50
Sofia 50
Westminster 50
Abidjan 47
Amman 45
Medford 43
Padova 43
Abeokuta 41
Milan 40
Bremen 33
Berlin 32
Brussels 31
Redmond 30
Redwood City 30
Bern 28
Jakarta 28
Helsinki 26
Turin 25
Saint Petersburg 21
Hebei 20
San Diego 20
Jinan 19
Shenyang 19
Florence 18
Lappeenranta 18
Nanchang 17
Guangzhou 16
Rome 16
Toronto 15
Jiaxing 14
Los Angeles 14
Changsha 12
Hong Kong 10
Paris 10
Zhengzhou 10
Busseto 9
Falls Church 9
Shanghai 9
Wuhan 9
Dearborn 8
Forlì 8
Hyderabad 8
Athens 7
Hangzhou 7
London 7
Monmouth Junction 7
Norwalk 7
Tianjin 7
Tokyo 7
Istanbul 6
Leawood 6
Ningbo 6
Phoenix 6
Romainville 6
Taizhou 6
Vienna 6
Andover 5
Augusta 5
Bo 5
Chengdu 5
Haikou 5
Irvine 5
Kilburn 5
Kolkata 5
Madrid 5
Mannheim 5
Moscow 5
Mountain View 5
Shenzhen 5
Wenzhou 5
Bari 4
Bitola 4
Bühl 4
Des Moines 4
Falkenstein 4
Fremont 4
Fuzhou 4
Henderson 4
Lanzhou 4
Muizenberg 4
Totale 5.580
Salva come PNG Salva come JPEG
Nome #
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 282
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 237
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 230
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 221
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 195
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 194
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 188
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 187
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 179
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 175
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 172
Co-occurrence of alterations in the DNA damage repair genes synergize with uncontrolled proliferation and associate with very-poor prognosis in acute myeloid leukemia patients 169
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 164
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 159
Bromodomain Inhibition Is Effective Against Acute Myeloid Leukemia Cells Under Hypoxia and Induces Genome-Dependent Metabolic Perturbations 151
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 145
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 144
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 143
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 132
Ex-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 132
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 132
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 130
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 129
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 127
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 127
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 124
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 124
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 122
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 122
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 122
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 120
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 120
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway 120
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 119
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 115
Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT) 111
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 109
You have accessEx-Vivo Drug Response Profiling for Precision Medicine Approaches in Acute Myeloid Leukemia with the Open Microwell Microfluidic Platform 109
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 107
SNP array reveals a new deletion of JAK2 in AML patients 107
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 106
Enhance the Efficacy of Doxorubicin Destabilizing the G2/M Checkpoint with a CHK1/CHK2 Inhibitor Pre-Treatment on Acute Lymphoblastic Leukemia 105
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 105
Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels 105
Override the doxorubicin-induced G2/M checkpoint using cell-cycle checkpoint inhibitors on acute lymphoblastic leukemia 93
A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination 93
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 92
Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia 92
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 91
Genomic wide microarray analysis identifies novel copy number alterations in adult acute myeloid leukemia 91
Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy 86
New JAK2 heterozygous loss: A role in overall survival in acute myeloid leukemia patients 84
Pharmacological interaction and side effects in oncohaematology: a retrospective observational study 78
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia 73
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant 73
Synergism through WEE1 and CHK1 inhibition in acute lymphoblastic leukemia 71
Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients 62
INCB84344-201: Ponatinib and steroids in frontline therapy of unfit patients with Ph+ acute lymphoblastic leukemia 62
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 61
Pharmacological inhibition of wip1 sensitizes acute myeloid leukemia cells to the mdm2 inhibitor nutlin-3a 59
Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment 54
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 53
Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia 53
Uncovering the expression of circPVT1 in the extracellular vesicles of acute myeloid leukemia patients 50
Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement 49
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia 34
ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment 34
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 30
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol 27
Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations 27
Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a 26
Hemophagocytic lymphohistiocytosis in gastric cancer: A rare syndrome for the oncologist. Case report and brief review 25
Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (Nature Communications, (2021), 12, 1, (6233), 10.1038/s41467-021-26551-x) 21
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease 21
Novel insights and therapeutic approaches in secondary AML 21
Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia 20
Personalizing precision medicine: Patients with AML perceptions about treatment decisions 19
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies 18
Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy 17
Safety of FLT3 inhibitors in patients with acute myeloid leukemia 16
INO-CD22: A Multi-Center, Real-Life Study on Inotuzumab-Ozogamicin Safety and Effectiveness in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia 15
Novel approaches for hematopoietic stem cell mobilisation and collection need to be assessed for qualification and validation to accomplish the proper requirements of their intended purpose 15
Editorial: Precision medicine for acute myeloid leukemia 14
Biological therapy in elderly patients with acute myeloid leukemia 14
Acute myeloid leukemia mutations: Therapeutic implications 14
The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia 13
Outcome of adult acute myeloid leukemia patients with extramedullary disease and treatment with venetoclax / hypomethylating agents 12
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia 12
The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials 9
Totale 8.410
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.980
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.980
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020837 0 0 0 0 0 112 149 159 171 108 83 55
2020/20211.418 126 40 25 18 33 62 33 93 96 34 84 774
2021/20221.502 160 35 70 145 129 72 46 120 76 105 305 239
2022/20231.834 206 261 96 222 164 134 60 96 310 49 139 97
2023/2024669 22 66 48 71 31 139 61 65 42 46 49 29
2024/20251.150 88 369 207 187 220 79 0 0 0 0 0 0
Totale 8.410